A precompetitive consortium for the twenty hardest cancer targets
No single company will spend a decade on a target that might be impossible. A shared, openly published effort across the twenty hardest targets spreads that risk.
The Structural Genomics Consortium showed that open chemical probes, published without patent restrictions, accelerate whole fields. The proposal is an oncology equivalent focused on the undruggable list (MYC, mutant p53, non-G12C RAS, fusion transcription factors, phosphatases), with pooled funding from several companies and funders, mandatory open data, milestone-based go/no-go, and freedom to operate for downstream drug development.
- The undruggable drivers · The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
Pages like this
not linked directly; found by shared links- IdeaAn open map of which cancer proteins any drug can stick to
Shares The Institute of Cancer Research, Broad Institute of MIT and Harvard, The undruggable drivers.
- InstitutionWorldwide Cancer Research
Shares Funding follows fashion, not burden, Cancer Research UK.
- IdeaAttack the backup copy when a tumour has lost the original gene
Shares The Institute of Cancer Research, Broad Institute of MIT and Harvard, The undruggable drivers.
- IdeaBreak up the liquid droplets where oncogenic transcription happens
Shares Broad Institute of MIT and Harvard, The undruggable drivers.
- IdeaPublish per-patient trial cost benchmarks and target halving them
Shares Funding follows fashion, not burden, Cancer Research UK.
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Secrecy and intellectual property block collaboration, Funding follows fashion, not burden.
- IdeaA public registry of unanswered clinical questions linked to funding calls
Shares Funding follows fashion, not burden, Cancer Research UK.
- IdeaScale up public drug development that takes academic assets to phase 1
Shares The Institute of Cancer Research, Cancer Research UK, The undruggable drivers.